<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444742</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0660</org_study_id>
    <secondary_id>NCI-2011-03436</secondary_id>
    <nct_id>NCT01444742</nct_id>
  </id_info>
  <brief_title>Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, or Are Refractory to, Hypomethylator Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if clofarabine when given in combination
      with cytarabine can help to control myelodysplastic syndrome (MDS) after the disease could
      not be controlled with standard therapy. The safety of this treatment will also be studied.

      Clofarabine is designed to interfere with the growth and development of cancer cells.

      Cytarabine is designed to insert itself into DNA (the genetic material of cells) of cancer
      cells and stop the DNA from repairing itself.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction Cycles:

      If you are found to be eligible to take part in the study, on Days 1-5 of each cycle , you
      will receive clofarabine by vein over 1-2 hours.

      On Days 1-7 of each cycle, you will receive cytarabine by injection under the skin over
      several seconds 2 times a day.

      You may receive up to 3 cycles at this dose and schedule (also called &quot;induction cycles&quot;).
      There are 7 treatment days in each cycle but the total length of one cycle (including rest
      and recovery period) is usually between 4 and 8 weeks.

      Consolidation Cycles:

      After you have completed the Induction Cycles, if you show a response to treatment, you can
      then continue with up to a total of 12 more cycles of therapy, which will be called
      &quot;consolidation cycles&quot;. Not every participant may be able to receive all 12 consolidation
      cycles. The actual number that you will receive depends on whether or not you maintain the
      response and how you are able to tolerate ongoing therapy. There will be 4-8 weeks between
      each consolidation cycle depending on any side effects you may be having and your blood
      counts.

      During consolidation cycles you will receive clofarabine on Days 1-3 by vein over 1-2 hours.
      You will receive cytarabine by injection under the skin over several seconds 2 times a day .

      Induction and Consolidation Cycles:

      On the days when you receive clofarabine and cytarabine (Days 1-5 during induction and Days
      1-3 during consolidation), the clofarabine will be given about 3-6 hours before the
      cytarabine injections. You can be taught to give cytarabine injections to yourself. In this
      case, you can leave the clinic after receiving clofarabine. You will be required to record
      the injections of cytarabine in a diary unless you receive the treatments while you are in
      the hospital.

      Study Visits:

      On Day 1 of every cycle (+/- 7 days):

        -  You will have a physical exam, including measurements of your weight and vital signs.

        -  Your performance status will be recorded.

        -  Blood (about 1-2 teaspoons) will be drawn for routine tests.

      About 4 weeks after you started your first cycle, you may have a bone marrow aspirate to
      check the status of the disease. After that, you may have repeat bone marrow aspirates when
      the doctor thinks it is needed.

      It is recommended that you stay in Houston for up to the first 4 weeks of treatment. After
      that, you will need to return to Houston before each induction cycle. If you continue with
      the consolidation you can receive these treatments by your local oncologist. However, you
      have to return to Houston at least every 3 months for your study visits.

      Length of Study:

      You may continue taking the study drugs for up to 15 cycles. You will no longer be able to
      take the study drugs if the disease gets worse, if intolerable side effects occur, or if you
      are unable to follow study directions.

      This is an investigational study. Clofarabine is FDA approved and commercially available for
      use in pediatric patients with acute lymphoblastic leukemia. Its use in adults and in
      patients with MDS is investigational.

      Cytarabine is FDA approved and commercially available for use in patients with acute myeloid
      leukemia (AML).

      Up to 80 patients will take part in this study. All be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2011</start_date>
  <completion_date type="Actual">January 29, 2017</completion_date>
  <primary_completion_date type="Actual">January 29, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Complete Response (CR)</measure>
    <time_frame>4 weeks after first cycle</time_frame>
    <description>Complete Response Criteria (CR must last for at least 4 weeks): Marrow: &lt;/= 5% myeloblasts with normal maturation of all cell lines; Persistent dysplasia noted; Blood: Hemoglobin (Hb) &gt;/= 11 g/dL (untransfused, patient not on EPO); Neutrophils &gt;/= 1x109/L (not on myeloid growth factor); Platelets &gt;/= 100 * 109/L (not on thrombopoietic agent); No blasts. Bone marrow aspirate and/or biopsy at the end of course 1 (day 28 +/- 7 days). The method of Thall, Simon, and Estey used to monitor response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival defined as the time interval from study entry date to the date of death due to any cause, measured in days/months. Bayesian time-to-event model used to monitor overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Leukemia</condition>
  <condition>Myeloproliferative Diseases</condition>
  <arm_group>
    <arm_group_label>Clofarabine + Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Induction:
10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)
Consolidation:
10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)</description>
    <arm_group_label>Clofarabine + Cytarabine</arm_group_label>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Induction:
20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
20 mg subcutaneously twice daily for 5 days (days 1-5)</description>
    <arm_group_label>Clofarabine + Cytarabine</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine Arabinosine Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;/= 18 years.

          2. Diagnosis of MDS confirmed within 10 weeks prior to study entry according to World
             Health Organization (WHO) or French-American-British (FAB) criteria. Patients are
             either not eligible for or choose not to proceed with a stem cell transplant.

          3. MDS classified as follows: refractory anemia with excess blasts (RAEB-1) (5%-9% BM
             blasts); RAEB-2 (10%-19% BM Blasts); chronic myelomonocytic leukemia (CMML) (5%-19%
             Bone Marrow (BM) blasts); RAEB-t (20%-29% BM blasts) AND/OR by International Prostate
             Symptom Score (IPSS): intermediate-2 and high risk patients.

          4. No response, progression, or relapse (according to 2006 International Working Group
             (IWG) criteria; see section 8 for details) following at least 4 cycles of either
             azacitidine or decitabine, or following at least 2 cycles of SGI-110, which were
             completed within the last 2 years - AND/OR - intolerance to azacitidine, decitabine,
             or SGI-110 defined as drug-related &gt;/= grade 3 hepatic or renal toxicity leading to
             treatment discontinuation during the preceding 2 years.

          5. Eastern Cooperative Oncology Group (ECOG) performance status of &lt;/= 2.

          6. Willing to adhere to and comply with all prohibitions and restrictions specified in
             the protocol.

          7. Patient (or patient's legally authorized representative) must have signed an informed
             consent document indicating that the patient understands the purpose of and procedures
             required for the study and is willing to participate in the study.

        Exclusion Criteria:

          1. Uncontrolled intercurrent illness including, but not limited to, symptomatic
             congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.

          2. Active infection not adequately responding to appropriate antibiotics (i.e. ongoing
             temperatures of &gt;/= 38 degree Celsius).

          3. Total bilirubin &gt;/= 1.5 mg/dL and not related to hemolysis or Gilbert's disease.
             Patients with total bilirubin &gt;/= 1.5 mg/dL to 3 mg/dL are eligible if at least 75% of
             the bilirubin is indirect.

          4. Alanine transaminase (ALT/SGPT) or aspartate transaminase (AST/SGOT) &gt;/= 2.5 x the
             upper limit of normal.

          5. Serum creatinine &gt; 1.5 mg/dL.

          6. Female patients who are pregnant or lactating.

          7. Patients with reproductive potential who are unwilling to following contraception
             requirements (including condom use for males with sexual partners, and for females:
             prescription oral contraceptives [birth control pills], contraceptive injections,
             intrauterine devices (IUD), double-barrier method [spermicidal jelly or foam with
             condoms or diaphragm], contraceptive patch, or surgical sterilization) throughout the
             study.

          8. Female patients with reproductive potential who do not have a negative urine or blood
             beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening.

          9. Patients receiving any other concurrent investigational agent or chemotherapy,
             radiotherapy, or immunotherapy.

         10. No prior treatment with cytarabine or clofarabine. Prior hydroxyurea for control of
             leukocytosis or use of hematopoietic growth factors (eg, G-CSF, Granulocyte-macrophage
             colony-stimulating factor (GM-CSF), procrit, aranesp, thrombopoietins) is allowed at
             any time prior to or during study if considered to be in the best interest of the
             patient.

         11. Psychiatric illness or social situation that would limit the patient's ability to
             comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Garcia-Manero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <results_first_submitted>March 13, 2018</results_first_submitted>
  <results_first_submitted_qc>May 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2018</results_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myeloproliferative Diseases</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>(MDS)</keyword>
  <keyword>Relapsing</keyword>
  <keyword>Refractory</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>Clofarex</keyword>
  <keyword>Clolar</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine Arabinosine Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 15, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01444742/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 11/2011 to 10/2015</recruitment_details>
      <pre_assignment_details>Of the 81 participants registered, one participant was never treated with the study medication. All Participants were registered at The University of Texas MD Anderson Cancer Center.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clofarabine + Cytarabine</title>
          <description>Induction:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)
Clofarabine: Induction:
10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)
Consolidation:
10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)
Cytarabine: Induction:
20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
20 mg subcutaneously twice daily for 5 days (days 1-5)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clofarabine + Cytarabine</title>
          <description>Induction:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)
Clofarabine: Induction:
10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)
Consolidation:
10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)
Cytarabine: Induction:
20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
20 mg subcutaneously twice daily for 5 days (days 1-5)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="30" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Complete Response (CR)</title>
        <description>Complete Response Criteria (CR must last for at least 4 weeks): Marrow: &lt;/= 5% myeloblasts with normal maturation of all cell lines; Persistent dysplasia noted; Blood: Hemoglobin (Hb) &gt;/= 11 g/dL (untransfused, patient not on EPO); Neutrophils &gt;/= 1x109/L (not on myeloid growth factor); Platelets &gt;/= 100 * 109/L (not on thrombopoietic agent); No blasts. Bone marrow aspirate and/or biopsy at the end of course 1 (day 28 +/- 7 days). The method of Thall, Simon, and Estey used to monitor response.</description>
        <time_frame>4 weeks after first cycle</time_frame>
        <population>One of the eighty-one participants registered on the study were in evaluable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine + Cytarabine</title>
            <description>Induction:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)
Clofarabine: Induction:
10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)
Consolidation:
10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)
Cytarabine: Induction:
20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
20 mg subcutaneously twice daily for 5 days (days 1-5)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response (CR)</title>
          <description>Complete Response Criteria (CR must last for at least 4 weeks): Marrow: &lt;/= 5% myeloblasts with normal maturation of all cell lines; Persistent dysplasia noted; Blood: Hemoglobin (Hb) &gt;/= 11 g/dL (untransfused, patient not on EPO); Neutrophils &gt;/= 1x109/L (not on myeloid growth factor); Platelets &gt;/= 100 * 109/L (not on thrombopoietic agent); No blasts. Bone marrow aspirate and/or biopsy at the end of course 1 (day 28 +/- 7 days). The method of Thall, Simon, and Estey used to monitor response.</description>
          <population>One of the eighty-one participants registered on the study were in evaluable for response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival defined as the time interval from study entry date to the date of death due to any cause, measured in days/months. Bayesian time-to-event model used to monitor overall survival.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clofarabine + Cytarabine</title>
            <description>Induction:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)
Clofarabine: Induction:
10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)
Consolidation:
10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)
Cytarabine: Induction:
20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
20 mg subcutaneously twice daily for 5 days (days 1-5)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival defined as the time interval from study entry date to the date of death due to any cause, measured in days/months. Bayesian time-to-event model used to monitor overall survival.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="0.5" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events captured from the time of participant consent until 30 days after the last dose of drug. AEâ€™s can be collected for up to 15 cycles.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clofarabine + Cytarabine</title>
          <description>Induction:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)
Clofarabine: Induction:
10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)
Consolidation:
10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)
Cytarabine: Induction:
20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
20 mg subcutaneously twice daily for 5 days (days 1-5)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pericardial Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Rectal Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Failure to Thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fever of Unknown Origin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infusion Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neck Mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Severe Deconditioning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated aspartate aminotransferase (AST)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pseudogout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Syncopal Event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Sweet Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Guillermo Garcia-Manero, MD/Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-745-3428</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

